MedTrace Logo

Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium

NCT05690698 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-08-30

No results posted yet for this study

Summary

In population of intensive care unit (ICU), most studies compared atypical antipsychotics such as quetiapine with the traditional haloperidol in delirious patients of various forms and etiologies. The role of such agents in patients with hyperactive is not fully understood.

This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity, length of stay in the intensive care unit, and mortality in critically ill patients.

Conditions

  • Hyperactive Delirium

Interventions

DRUG

Quatiapine

Atypical antipsychotic

DRUG

Haloperidol

Antipsychotic

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Tamer N. Habib, MD · University of Alexandria

  • Islam E. Ahmed, PharmD · Faculty of Medicine, Suez-canal University

  • Ibrahim K. Luttfi, PHD · Faculty of Medicine, Gezira University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-09
Primary Completion
2023-07-15
Completion
2023-07-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05690698 on ClinicalTrials.gov